This content is created by Smallcaps Authors. [Author : Danica Cullinane]
Immuno-oncology company Imugene (ASX: IMU) has collared a patent in the United States for its PD1-Vaxx immunotherapy for lung cancer, while clinical trials of its novel cancer-killing virus have progressed. Imugene is developing therapies, which are designed to activate a cancer patient’s immune system to fight its tumour cells. By essentially harnessing a patient’s own […]
The post Imugene locks-in patent for PD1-Vaxx immunotherapy, progresses cancer killing virus appeared first on Small Caps.
from Small Caps https://ift.tt/vy12JXd
إرسال تعليق